Unity Biotechnology, Inc. (NASDAQ:UBX – Free Report) – Stock analysts at HC Wainwright issued their Q1 2024 EPS estimates for Unity Biotechnology in a research report issued on Tuesday, April 16th. HC Wainwright analyst M. Caufield anticipates that the company will post earnings of ($0.57) per share for the quarter. HC Wainwright currently has a “Buy” rating and a $8.00 price target on the stock. The consensus estimate for Unity Biotechnology’s current full-year earnings is ($2.66) per share. HC Wainwright also issued estimates for Unity Biotechnology’s Q2 2024 earnings at ($0.59) EPS, Q3 2024 earnings at ($0.62) EPS, Q4 2024 earnings at ($0.64) EPS and FY2028 earnings at $0.29 EPS.
Unity Biotechnology Stock Performance
Unity Biotechnology stock opened at $1.51 on Wednesday. The stock has a 50-day simple moving average of $1.66 and a 200-day simple moving average of $1.78. The company has a market capitalization of $25.35 million, a P/E ratio of -0.51 and a beta of 0.87. Unity Biotechnology has a fifty-two week low of $1.50 and a fifty-two week high of $3.82.
Institutional Trading of Unity Biotechnology
Unity Biotechnology Company Profile
Unity Biotechnology, Inc, a biotechnology company, engages in the research and development of therapeutics to slow, halt, or reverse diseases of aging. The company's lead drug candidate includes UBX1325, which is phase II clinical trial for the treatment of age-related diseases of the eye, including diabetic macular edema, age-related macular degeneration, and diabetic retinopathy.
Recommended Stories
- Five stocks we like better than Unity Biotechnology
- Canadian Penny Stocks: Can They Make You Rich?
- Comprehensive PepsiCo Stock Analysis
- Following Congress Stock Trades
- CSX Co.: The Railroad Powering Ahead with an Earnings Beat
- What is the Dogs of the Dow Strategy? Overview and Examples
- Bear Market Funds to Watch This Year
Receive News & Ratings for Unity Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Unity Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.